• Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care.
• DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation.
• ETST is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services.

Telehealth is evolving from a simple video visit into something far more comprehensive: a connected care model that can move a patient from consultation to prescription, fulfillment and follow-up inside one digital pathway. That shift toward fully integrated platforms is changing expectations across healthcare, and Earth Science Tech’s (OTC: ETST) is building exposure to that trend through a portfolio that includes telemedicine platforms, compounding pharmacies and related healthcare services.

The logic behind integrated telehealth is straightforward. Patients increasingly want access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care. The American Medical Association’s telehealth integration toolkit notes that optimized virtual care workflows can improve patient care through more efficient delivery and better integration into routine practice.

The need for improved care and efficiency is reflected in the forecast for the telehealth space. DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation. “The telehealth market is largely propelled by the increasing prevalence of chronic diseases, which creates a growing demand for frequent medical consultations and ongoing patient monitoring, services that telehealth can effectively deliver,” the article noted. “Simultaneously, the broad adoption of smartphones, high-speed internet connectivity, and wearable health technologies supports smooth remote consultations and real-time health monitoring.

“Moreover, continuous product development by leading industry players is bringing advanced telehealth solutions to market, enhancing service quality and widening access to care,” the article continued. “Collectively, these factors are driving the expansion of telehealth, improving patient engagement and contributing to overall market growth.”

There is also a clinical and operational case for tighter integration. A 2025 study published in the “Journal of Health, Population and Nutrition” describes electronic prescribing as a key component of ehealth and says it can enhance healthcare efficiency, reduce errors, and support safer, more accurate medication management. A 2025 telepharmacy review similarly notes that remotely delivered pharmaceutical care can improve medication safety, strengthen continuity of care and reduce prescribing errors through structured pharmacist-led interventions. Together, those findings reinforce the core idea behind integrated telehealth platforms: Digital consultation becomes more valuable when it connects directly to medication management and care continuity rather than ending at the virtual visit.

At the same time, the rise of direct-to-consumer virtual care has raised questions about fragmentation. A 2026 scoping review of commercial virtual care found that such platforms have expanded rapidly over the past decade, but it also warned that virtual services not integrated into broader care systems can disrupt continuity of care and may increase utilization without improving outcomes. That tension helps explain why the “from consultation to prescription” model matters. The next competitive step is not just offering digital access; it is building a system where consultation, prescribing, pharmacy and follow-up are coordinated rather than isolated.

That broader industry trend provides useful context for Earth Science Tech. The company describes itself as a strategic holding company that acquires and actively manages operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and selected consumer markets. ETST’s healthcare-related holdings include telemedicine and pharmaceutical operations designed to support a more connected platform approach; in addition, its compounding operations through RxCompoundStore.com and Mister Meds directly align with the expanding digital healthcare segment.

Earth Science Tech recently reported that its operations include compounding pharmaceuticals, telemedicine, and real estate development through subsidiaries including RxCompoundStore.com, Mister Meds, Peaks Curative, DOConsultations, Las Villas Health Care, Avenvi, Earth Science Foundation and an 80% interest in MagneChef. That portfolio matters because it suggests the company is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services.

The telehealth angle becomes even more specific in descriptions of Peaks. Earth Science Tech described Peaks as a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds, noting that the platform operates in states where either pharmacy is licensed. The company also noted that it is building out its own healthcare provider network through MyOnlineConsultation.com while pursuing additional pharmacy licensure to expand the service footprint. That structure is a close fit with the “consultation to prescription” theme, because it links provider access, prescribing pathways and pharmacy capabilities under one corporate umbrella.

Earth Science Tech has also pointed to traction inside that model, noting that it is operating as a diversified portfolio across pharmaceutical, healthcare, telemedicine and consumer markets while emphasizing controlling interests, regulatory compliance, and disciplined scaling. Earlier this month, the company reported that Peaks had surpassed $2 million in revenue in less than a year and is pursuing additional state licenses. These reports suggest that ETST’s telemedicine-related assets are becoming commercially meaningful within the broader portfolio.

For investors, the company’s appeal in the telehealth space lies less in a pure-play software multiple and more in its attempt to build a vertically connected healthcare platform. ETST chairman and CEO Giorgio R. Saumat has described the business as a “a strategic holding company with core assets in healthcare, mostly compounding pharmaceuticals and online telehealth. We are creating a vertically integrated healthcare company. From the marketing side we have Peaks Curative, our online telehealth subsidiary, all the way through Mister Meds and RxCompoundStore.com that fulfill the patient.”

That framing is important because it aligns the company with a part of digital healthcare that could become increasingly valuable if the industry continues moving from isolated virtual appointments toward integrated models that can connect care access, medication prescribing and fulfillment.

As telehealth matures, the companies that stand out may be the ones that reduce friction after the appointment not just during it. Consultation alone is useful, but consultation linked to prescribing, pharmacy operations and follow-up can create a more complete care pathway. Earth Science Tech is working to build that kind of structure through its mix of telemedicine platforms, compounding pharmacy assets and healthcare subsidiaries, positioning itself within a digital care model that increasingly looks less like a video visit and more like an end-to-end service platform.

For more information, visit EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• Beeline Holdings Inc. has partnered with TYTL Corp. to support fractional equity transactions in U.S. residential real estate, and have already finalized 11 fractional equity acquisitions and launched an initial property portfolio.
• The product is branded at BeelineEquity and can be found on Beeline’s website representing a significant revenue opportunity for Beeline – Every $1B in transaction value represents $41M in revenue for Beeline.
• Tokenization model combines traditional and blockchain infrastructure, as property interests are deed-recorded through standard closings before being tokenized on-chain.
• Beeline’s digital mortgage, title, and closing infrastructure will facilitate scaling of the fractional equity model, with the initiative targeting a U.S. housing market estimated at $110 trillion in property value and roughly $39 trillion in homeowner equity.

Beeline Holdings (NASDAQ: BLNE),  a fast-growing digital mortgage platform redefining the path to homeownership, recently announced a collaboration with TYTL Corp., a company developing a blockchain-enabled system that tokenizes deed-recorded equity interests in residential real estate. Under the agreement, Beeline will support fractional equity acquisitions through its BeelineEquity platform while its subsidiary, Beeline Title, will act as the exclusive title and settlement provider for the transactions (https://ibn.fm/jRtpb).

The approach blends conventional real estate closing processes with blockchain verification. Ownership interests are recorded in local property registries through standard closings before TYTL mints digital tokens representing those interests. The partnership has already produced early results. The companies confirmed that the first 11 fractional real estate equity transactions have been completed, establishing an initial portfolio as they begin scaling the platform.

Tokenization has increasingly been explored as a mechanism to increase liquidity in traditionally illiquid asset classes, including real estate. By dividing ownership into fractional interests represented digitally, investors can participate in property ownership without acquiring entire properties.

In the Beeline–TYTL model, homeowners sell a portion of their property equity through a deed-recorded transaction rather than taking on a loan. The structure differs from products such as home equity lines of credit or reverse mortgages. Homeowners receive liquidity without monthly payments, accrued interest, or fixed maturity obligations. Instead, the transaction represents a partial sale of property ownership.

This framework aims to unlock value from residential real estate while preserving the underlying property structure recognized by local registries and traditional closing procedures. The opportunity is significant in scale. The companies estimate that the U.S. housing market represents approximately $110 trillion in property value, including roughly $39 trillion in homeowner equity that could potentially be accessed through alternative financial structures.

The partnership leverages the broader technology platform developed by Beeline. The company operates a digital-first mortgage ecosystem designed to streamline lending, underwriting, and closing. Its platform relies heavily on automation and artificial intelligence to reduce the time required to process mortgage transactions.

At the front end of the system is “Bob,” an AI-powered mortgage chatbot designed to guide borrowers through early stages of the mortgage process. According to the company, Bob can deliver eligibility assessments in minutes, providing borrowers with roughly 90% certainty about mortgage qualification within seven to eight minutes.

The company’s internal production engine, Hive, coordinates workflows across underwriting, loan processing, title coordination, and closing. Automation of these processes has allowed Beeline to reduce average loan closing timelines to approximately 14 to 21 days, compared with industry averages often exceeding a month.

Quality control is handled through BlinkQC, an internal AI-driven system designed to automate compliance and loan review functions. Title services are integrated through Beeline Title, allowing borrowers and investors to complete closings and escrow workflows within the same platform.

This integration is central to the TYTL partnership, as the tokenization model still requires conventional property closing procedures before blockchain representation occurs.

Beyond its tokenization initiative, Beeline’s mortgage platform targets two primary customer groups: younger homebuyers and real estate investors. Millennials and Gen Z borrowers face structural challenges entering the housing market. According to data cited by National Mortgage Professional, only 54.9% of millennials and 26.1% of Gen Z owned homes in 2024, largely due to limited access to mortgage financing (https://ibn.fm/eGKYf).

Beeline’s automated underwriting and digital workflow tools are designed to accelerate mortgage eligibility decisions, particularly for borrowers with nontraditional income patterns common in gig-economy employment. The company also originates loans for investment properties, offering products such as debt service coverage ratio (“DSCR”) loans and bank-statement loans commonly used by property investors. Management has noted that a significant portion of Beeline’s lending activity supports buyers acquiring rental or investment properties rather than primary residences.

The partnership with TYTL adds another layer to Beeline’s broader strategy by integrating blockchain-enabled equity products into its mortgage and title ecosystem. Fractional equity transactions will be facilitated through the BeelineEquity brand, while Beeline Title will handle settlement, escrow, and recording processes.

Once the transaction is completed through traditional closing infrastructure, TYTL publishes tokenized representations of the ownership interests on-chain. The companies say the system is designed to preserve the legal certainty of conventional property ownership while introducing digital infrastructure that may allow fractional ownership to scale more efficiently.

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Canadian mineral exploration company Powermax Minerals has reported soil and rock sampling results indicating rare earth element mineralization at the Cameron REE Project in British Columbia.
• Soil samples returned Total Rare Earth Oxide (“TREO”) values ranging from 135 ppm to 2,840 ppm, outlining a mineralized corridor more than one kilometre long, with rock sampling returning values up to 741 ppm TREO, supporting the potential presence of REE-bearing bedrock.
• Results suggest REE mineralization associated with NYF-type pegmatites, a geological setting known to host rare earth deposits, and identify multiple areas for follow-up exploration and potential drilling.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on critical rare earth elements, has reported encouraging early exploration results from its Cameron Rare Earth Element Project in British Columbia. Recent soil and rock sampling programs at the project have identified multiple areas of anomalous rare earth element mineralization associated with pegmatite systems, according to a company announcement (https://ibn.fm/oehFU).

The Cameron project is located roughly 40 kilometers south of Revelstoke in British Columbia, along Highway 23 near the Columbia River. The property spans approximately 2,984 hectares within the Kamloops Mining Division. Powermax recently conducted a soil geochemical survey across priority areas of the property. The program returned Total Rare Earth Oxide (“TREO”) values ranging from approximately 135 parts per million to 2,840 ppm, with an average value of about 340 ppm TREO. Several samples recorded anomalous values above 400 ppm TREO, and the highest sample reached 2,840 ppm TREO.

The results outlined a north–south trending corridor of elevated rare earth values extending for more than one kilometre. The anomalous zone coincides with mapped pegmatites and historically documented thorium-uranium mineralization associated with the Cameron (Jenkins) showing areas.

Clusters of the strongest anomalies occur within the Cameron REE 2 claim block, suggesting a potential bedrock source of rare earth mineralization beneath shallow overburden.

Follow-up prospecting programs focused on exposed pegmatite outcrops and mineralized float across the property. Surface rock sampling returned TREO values ranging from less than 36 ppm to 741 ppm TREO, with several samples exceeding 100 ppm TREO. The highest value recorded was 741 ppm TREO, while additional samples returned values between 526 ppm and 741 ppm TREO.

These anomalous rock samples cluster in areas along the Highway 23 corridor within the Cameron REE 3 claim block, as well as near the Cameron (Jenkins 1) showing.

The spatial relationship between soil anomalies and mineralized rock samples suggests the presence of rare earth-bearing pegmatite bodies in bedrock underlying the geochemical anomalies. Because the samples were selective grab samples, they are not considered representative of average mineralization grades across the property.

The exploration results point toward mineralization associated with NYF-type pegmatites, a class of pegmatites enriched in elements such as niobium, yttrium, fluorine and rare earth elements. These pegmatites occur within the broader Monashee geological terrane, a metamorphic and granitic region known to host pegmatitic intrusions and structurally controlled mineralization.

At Cameron, rare earth mineralization appears linked to shear zones and pegmatite intrusions enriched in both light rare earth elements (“LREE”) and heavy rare earth elements (“HREE”). According to the company, the correlation between soil anomalies, rock sampling results, and previously reported stream sediment results strengthens the exploration model for the project.

Management says the next phase of exploration will focus on identifying the underlying bedrock sources responsible for the surface geochemical anomalies. Future programs may include additional mapping, trenching, and drilling to test the most prospective targets.

Powermax’s Chief Executive Officer Paul Gorman reiterated the importance of the Cameron Property results by stating. “The strong correlation between soil geochemical anomalies and anomalous REE values from surface rock and previously reported stream sediment sampling indicates the potential for a pegmatite system prospective for REE mineralization on our property. Our upcoming exploration program will focus on defining the bedrock sources of these anomalies and advancing the most prospective targets toward drilling.” 

Powermax’s exploration work comes as governments and industries are seeking alternative supply chains for rare earth elements used in advanced technologies. Rare earth elements are essential components in electric vehicle motors, wind turbines, electronics and defense systems.

Global demand for rare earth oxides is projected to rise significantly in the coming decade, driven in part by the electrification of transportation and expansion of renewable energy infrastructure. 

At present, China controls a large share of global rare earth production and an even larger portion of processing capacity. This concentration has prompted Western governments to support the development of domestic or allied supply chains. In the United States, for example, federal initiatives under the Defense Production Act have directed more than $1 billion toward strengthening rare earth supply chains and supporting new production. Canadian projects are also viewed as potential contributors to future North American supply.

In addition to the Cameron project, Powermax Minerals Inc. holds exploration interests in several rare earth projects across North America. These include the Atikokan REE property in northwestern Ontario and the Pinard REE project in northern Ontario. The company also owns a 100% interest in the Ogden Bear Lodge Project in Wyoming.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

• High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology.
• Soligenix is leveraging its platform science to expand the therapeutic reach of its development programs and explore additional disease indications.
• The broader emphasis of Soligenix’s platform science approach is to maximize the scientific value of its research infrastructure.

Medical progress has transformed the treatment of many common illnesses, yet thousands of rare diseases still lack effective therapies. Companies working at the intersection of biotechnology innovation and rare disease research are increasingly focused on addressing these gaps, including Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing and commercializing therapies and vaccines for rare diseases and unmet medical needs.

The need for sustained development in rare disease medicine is significant. While each condition may affect a relatively small number of individuals, the collective impact is significant. According to the U.S. National Institutes of Health, rare diseases affect an estimated 25 million to 30 million Americans, illustrating that these conditions represent a major public-health challenge despite their individual rarity. Similarly, the U.S. Food and Drug Administration reports that more than 10,000 rare diseases have been identified, affecting roughly one in ten people in the United States.

Despite this widespread impact, therapeutic development remains limited — and essential. The National Organization for Rare Disorders notes that only a small fraction of rare diseases currently have approved treatments, leaving the majority of patients without targeted therapeutic options. Developing therapies for these conditions can be particularly challenging because patient populations are small and the underlying biology of many diseases is not yet fully understood. Clinical trials are often more complex to design and conduct, requiring innovative scientific approaches and specialized expertise.

For these reasons, high-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. By leveraging platform technologies, companies can apply core scientific capabilities across multiple therapeutic programs, improving efficiency and enabling the exploration of treatments for diseases that might otherwise remain neglected. These approaches can accelerate the discovery and development process, making it more feasible to address smaller patient populations while maintaining rigorous standards for safety and efficacy.

Soligenix is among the companies applying this platform-driven strategy to rare disease research. The company is leveraging its platform science to expand the therapeutic reach of its development programs and explore additional disease indications. The strategy reflects a broader effort to build on core technologies that can support multiple product candidates across different rare and neglected conditions.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases as well as certain inflammatory and infectious conditions. The company’s development programs span two primary segments: specialized biotherapeutics and public health solutions. Within the rare disease category, its pipeline includes therapies designed to address conditions that currently have limited treatment options.

The company’s strategy centers on leveraging established scientific platforms that can be adapted for multiple therapeutic applications. By using a platform-based approach, Soligenix aims to streamline development while expanding the potential reach of its technologies. This method allows researchers to apply existing expertise and scientific insights to new disease targets, potentially accelerating progress across multiple programs simultaneously.

Among the company’s notable development efforts is HyBryte(TM), a photodynamic therapy designed for the treatment of cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma that affects the skin. The therapy combines synthetic hypericin with visible light activation and has been studied as a novel approach for treating early-stage disease. Programs such as this highlight the company’s focus on rare and difficult-to-treat conditions where new therapeutic approaches could provide meaningful benefits for patients.

Beyond individual programs, the broader emphasis of Soligenix’s platform science approach is to maximize the scientific value of its research infrastructure. By applying core technologies across multiple programs, the company seeks to enhance development efficiency while supporting the exploration of additional therapeutic indications. This strategy may enable the company to pursue multiple rare disease opportunities while maintaining a focused research framework.

The company’s platform capabilities allow it to extend scientific insights beyond a single therapy or disease target. In practice, this means that discoveries or innovations developed in one program can potentially inform additional research areas, creating opportunities for expanded therapeutic development. Such cross-program synergy is increasingly important in rare-disease research, where scientific breakthroughs often depend on specialized knowledge and long-term investment.

As biotechnology innovation continues to evolve, platform-driven development strategies are becoming a defining feature of companies working in rare disease medicine. The ability to build multiple therapies from a shared scientific foundation can improve development efficiency and broaden the potential impact of research investments.

For Soligenix, leveraging platform science represents a pathway toward expanding its pipeline while continuing to focus on diseases that historically have received limited attention. By combining specialized research capabilities with a platform-based development model, the company is positioning itself to pursue new therapeutic opportunities while contributing to the broader effort to address the unmet medical needs faced by patients with rare diseases.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising.

• Recent analysis by Zacks Small Cap Research underscores the positive strategic position of Canadian gold developer LaFleur Minerals as it prepares to restart gold production at its Beacon Gold Mill this year
• LaFleur’s assets include its wholly owned Beacon Gold Mill, nearby district-scale Swanson Gold Deposit within the renowned Abitibi belt, and a strategic proximity to skilled labor and equipment suppliers in the already established Val d’Or, Quebec mining camp
• LaFleur recently completed a Preliminary Economic Assessment (“PEA”) that outlining the potential for profitability thanks to its scalable mining project and established processing infrastructure, highlighted by a rapid payback period and capital efficiency with expected 65% IRR after taxes
• LaFleur updated its 2024 mineral resource estimate (“MRE”) with a 30% increase in the indicated MRE category to over 160,000 ounces of contained gold, and to over 66,000 ounces of contained gold in the inferred category

A recently completed Preliminary Economic Assessment (“PEA”) is substantiating near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF)‘s profile as a junior gold developer positioned to capitalize on the pairing of its scalable Swanson Gold Deposit and its fully permitted Beacon Gold Mill in Eastern Canada’s Tier‑1 Abitibi gold belt, as it prepares to restart gold production during Q2-2026.

The PEA highlights the project’s capital efficiency and economic returns that are anticipated to be significant, particularly at market prices recorded throughout 2025 and into 2026. The PEA establishes a Net Present Value (“NPV”) of C$101 million (5% value creation) and places Internal Rate of Return (“IRR”) expectations at 65% after taxes — highlighting a potential investment profitability that features quick payback and a competitive base-case IRR when compared to peers.

The PEA’s All-In Sustaining Costs (“AISC”) conservative metric sustains that even if gold prices trending around $5,000 per ounce this year were to retreat as far as $2,750 per ounce, the project would remain profitable. “For investors, the combination of a validated mine plan, a permitted processing facility, and a strengthening gold market creates a compelling setup for value realization over the next 12–24 months,” recent analysis by Zacks Small Cap Research states (https://ibn.fm/swGNK).

“Operational readiness is another differentiator,” the report adds. “The Beacon Gold Mill is fully permitted, refurbished, and funded for restart following a C$7 million financing. … With multiple catalysts ahead, including ongoing drill results, bulk sample approval, and mill commissioning, the company is positioned for a meaningful re-rating as it advances toward production.”

The company’s updated 2026 mineral resource estimate (“MRE”) preceded positive results from recently completed diamond drilling but still increased the indicated mineral resource from the 2024 findings by 30% to ~160,300 ounces of contained gold in the indicated category and ~66,800 ounces of contained gold in the inferred category (https://ibn.fm/ylqOi).

The indicated resource favors the company’s open pit strategy at low operational cost over years compared to the eventual transition to exploring the project’s underground potential. The mineralized footprint remains “open in all directions, and ongoing drilling continues to demonstrate extensions at depth, on strike, and internally within the deposit,” Zacks notes.

LaFleur is focused on continued technical optimization, metallurgical and bulk sample validation, and permitting advancement for restarting gold production at the Beacon Mill this year, with about 30% of the budget spent to ready the facility for a planned gold pour in the coming months.

The strategy establishes LaFleur Minerals as a company with a clear path to production, existing processing assets and the potential for pipeline resource growth.

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties, recently announced launch of a 70 km² district-scale ANT survey at its flagship Montauban Gold-Silver Project in Québec
• This marks the second phase of the survey, with the initial one having covered 10 km², completed in 2025
• The expanded program is to confirm whether the interpreted structural corridor continues along strike, and marks a pivotal stage for the company in understanding the broader geological framework of Montauban
• ESGold also closed its recent LIFE Offering, raising gross proceeds of C$7.2 million

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, announced the launch of a 70 square kilometers district-scale Ambient Noise Topography (“ANT”) survey at its flagship Montauban Gold-Silver Project in Québec. It represents the second phase of a survey, which originally covered only 10 km² and was completed in 2025. Results from this initial survey formed the basis of ESGold’s integrated 3D geological model, which has been integral in highlighting Montauban’s full potential (https://ibn.fm/iCgW4).

“This next phase marks an important step in defining the full scale of Montauban,” noted Gordon Robb, ESGold’s CEO.

“Our initial ANT survey and integrated 3D model revealed a deep and expanding mineralized corridor extending to approximately 900 meters and over at least two kilometers of strike. The expanded 70 square kilometer program is seven times larger than our initial survey and represents the most comprehensive geophysical assessment ever conducted across the Montauban district,” he added (https://ibn.fm/iCgW4).

This expanded survey program looks to confirm whether the interpreted structural corridor continues along strike. It is also designed to assess the potential for additional mineralized lenses within the broader framework. It will deliver high-resolution, three-dimensional subsurface imaging across a significant portion of the company’s newly consolidated land package. It will also help define high-priority drill targets for future exploration, while further assessing the size, shape, and continuity of mineralized anomalies.

“For the first time in the project’s history, this land package has been consolidated under one operator and is being evaluated using modern, deep-penetrating geophysical tools,” Robb noted. “We believe we are at a pivotal stage in understanding the broader geological framework of Montauban,” he concluded (https://ibn.fm/iCgW4).

The company also recently announced the closing of its brokered LIFE offering, raising gross proceeds of C$7.2 million. The offering involved the sale of 10,683,000 units of the company at C$0.68 per unit, with Red Cloud Securities Inc. acting as the sole agent and bookrunner. ESGold intends to direct the net proceeds from the offering to the advancement of its Montauban project, as well as general working capital and corporate purposes. 

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Security and defense company Safe Pro Group recently announced that it has executed full delivery of the company’s AI-powered edge processing systems to the U.S. Government.
• The delivery proved that the company can rapidly execute contracts under U.S. Government programs, as it delivered these systems 15 days after the receipt of the award.
• SPAI also announced that the company’s subsidiary, Airborne Response, LLC, has gotten a purchase order from a multinational telecommunications firm to provide aerial inspections and asset management services.

Safe Pro Group (NASDAQ: SPAI), a tech company that delivers security and defense solutions, recently announced that it has completed the full delivery of the company’s AI-powered edge processing systems valued at $1 million to the U.S. Government (https://ibn.fm/hNZEA). Safe Pro Group’s AI-powered edge processing systems are tactical, hardware-based units able to analyze drone imagery and sensor data quickly in communication-restricted or denied environments.

The company executed this delivery just 15 days after receiving the award, representing an operational milestone as SPAI as it advances commercialization of its patented AI product portfolio.

Speaking about the delivery, Safe Pro Group CEO, Dan Erdberg, said “Delivering in 15 days from the receipt of our award demonstrates Safe Pro’s ability to rapidly execute on contracts under U.S. Government programs, building confidence in our capabilities and establishing a critical past performance track record with customers.”

Following this contract, Safe Pro continues to pursue additional opportunities with U.S. Government agencies, prime contractors, and allied international partners.

In addition to completing this delivery, SPAI’s Mission Critical Unmanned Solutions subsidiary, Airborne Response, LLC, has received a purchase order from a multinational telecommunications firm (https://ibn.fm/IakcE). The company has been tasked with providing unmanned aircraft systems (“UAS”) aerial inspection and asset management services supporting communication infrastructure that’s used by first responders in South Florida. Under the program, Airborne Response will deploy FAA-compliant UAS flight teams to conduct comprehensive aerial inspections of emergency communication towers. The company will inspect antennas, connections, and structural components, while also providing georeferenced imaging, asset documentation, and power line pathway inspections to support operational readiness.

These inspections are designed to make sure the radio communications infrastructure that first responders rely on are both reliable and resilient. This engagement expands Safe Pro’s operational rollout of the company’s drone-based intelligence platform and builds on SPAI’s strategy to build one of the industry’s largest real-world aerial data pipelines to support next-gen computer vision AI models.

Speaking about the purchase order, Erdberg said “This purchase order, supporting vital communications infrastructure, highlights the increasing role of drone technology in mission-critical public safety operations, and importantly, provides us with a unique opportunity to utilize our drone services to directly fuel the growth of our AI platform with real world data.”

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that develops and delivers security and defense solutions to customers in the humanitarian, law enforcement, homeland security, defense, and commercial markets. At the core of SPAI’s mission is the company’s patented computer vision technology that rapidly detects and identifies small explosive objects in drone footage, to enable safer and more efficient field operations for teams on the ground.

For more information, visit the company’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

• Eight new patent applications have been filed covering reactor geometry, electromagnetic confinement, and control systems related to the Texatron(TM) fusion platform for energy generation, securing protection across reactor architecture, fuel management, and integrated energy systems as the company’s fusion technology development progresses.
• The company’s strategy focuses on generating revenue through energy partnerships and contractual structures in advance of full fusion power deployment.
• Electrical engineer Andrew S. Mikulski has joined the board as an independent director.
• Energy markets specialist Sebastian E. Hoyos has been appointed Chief Revenue Officer to lead commercialization strategy.

Renewal Fuels (OTC: RNWF) (d/b/a American Fusion), an advanced energy platform company focused on the development and commercialization of fusion energy technologies, is expanding its intellectual property portfolio and leadership team as it pursues the development and commercialization of its Texatron(TM) fusion energy platform.

The Texas-based company recently announced the filing of eight additional patent applications with the U.S. Patent and Trademark Office related to the Texatron reactor architecture (https://ibn.fm/WRGDr). The new applications cover several technical components of the reactor system, including toroidal chamber designs, clamshell housing structures, electromagnetic confinement elements, and electronic control systems that regulate pulsed energy inputs.

Management said the filings expand the intellectual property framework supporting the Texatron architecture, which is being developed as a modular fusion system intended for eventual industrial and grid applications.

The patent expansion forms part of a broader strategy to secure layered protection across several aspects of the technology. According to the company, the intellectual property approach targets multiple areas, including reactor geometry, electromagnetic confinement methods, fuel cycle management, and integrated system design. These protections are intended to evolve alongside engineering development and eventual commercial deployment.

Brent Nelson, chief executive of Kepler Fusion Technologies, said the patent portfolio is being built to align with ongoing design refinements. “Our intellectual property strategy is being built deliberately around the core architecture of the Texatron system,” Nelson said in the company update. Each patent filing is intended to protect structural and system-level elements of the reactor design while supporting future commercialization options. “As development progresses, we expect the portfolio to continue expanding in parallel with ongoing engineering refinement and validation,” Nelson added. 

The company previously disclosed that twenty patent applications had already been filed covering key structural and electromagnetic aspects of the Texatron platform. The additional filings bring the portfolio further along as development work continues.

Alongside the patent update, the company announced two senior appointments aimed at strengthening governance and commercialization capabilities.

The first is the appointment of Andrew S. Mikulski as an independent member of the board of directors. Mikulski, an electrical engineer with experience in power electronics and advanced electrical systems, joined the board effective March 6, 2026.

He currently serves as product manager for magnetics, sensors and actuators at KEMET Electronics Corporation, a subsidiary of Yageo Corporation. In that role, he oversees electromagnetic component technologies used in power conversion systems, industrial automation platforms, and sensing applications. Earlier in his career, Mikulski worked as an electrical engineer at Textron Systems, where he contributed to testing and integration work on defense technology platforms. He also serves as co-chair of the Power Sources Manufacturers Association capacitor committee, where he participates in technical collaboration and industry standards development.

Company leadership said his background in electrical system architecture and high-reliability engineering will provide technical oversight at the board level as the Texatron platform advances. 

Richard Hawkins, chief executive of Renewal Fuels, said the appointment strengthens the board’s technical perspective as the company develops its fusion system. “Andrew brings a strong engineering foundation and practical experience working with complex electrical systems used in demanding environments such as aerospace, defense, and industrial infrastructure,” Hawkins said. “As the company continues advancing the Texatron platform, having board level oversight from individuals who understand power electronics, system architecture, and engineering commercialization adds meaningful depth to the company’s governance and technical perspective.”

The company also moved to expand its commercial leadership by appointing Sebastian E. Hoyos as Chief Revenue Officer (https://ibn.fm/T4eE2). Hoyos brings more than fifteen years of experience structuring bankable commercial energy agreements across regulated and deregulated electricity markets. His work has focused on developing long-term power purchase agreements and energy supply contracts with corporate and institutional energy buyers.

Prior to joining American Fusion, Hoyos served as head of renewable energy solutions at Diverxia, where he led corporate energy origination efforts and negotiated power offtake agreements. Earlier roles included heading renewable energy strategy for the Americas at ENGIE Impact and managing a large portfolio of renewable energy contracts during his tenure at Walmart. At Walmart he oversaw more than four hundred energy agreements covering solar, wind, storage, fuel cells, and electric vehicle infrastructure projects.

The company said Hoyos will lead the commercialization strategy for the Texatron technology platform, including the development of energy partnerships and long-term contract structures. This commercial planning is intended to position the company for revenue opportunities prior to full technology deployment.

Management indicated that much of the administrative groundwork following the merger between Renewal Fuels and Kepler Fusion Technologies has been completed, allowing the company to shift greater focus toward product development and commercial strategy.

“Sebastian’s experience negotiating power purchase agreements and working across both regulated and deregulated energy markets provides valuable commercial expertise as we continue developing the Texatron platform,” Nelson said. “With much of our first quarter groundwork now behind us, we are keen to focus on uplisting to a listed exchange and are laser focused on building fundamental value and revenue in the company to enhance shareholder value.”

Hoyos underlined that the Texatron represents a paradigm shift in technology that only happens once in someone’s lifetime. “I truly believe this is the greatest invention since man harnessed fire. Fusion energy has the potential to redefine how the world produces and consumes power, and I look forward to building the revenue platform that will help bring this breakthrough technology to customers across the globe,” Hoyos added. 

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to RNWF are available in the company’s newsroom at https://ibn.fm/RNWF

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• Canamera Energy Metals recently confirmed elevated rare earth oxide values at its Iron Hills Project in Colorado, including assays up to 6,557 ppm TREO.
• EMETF operates at the nexus of critical minerals exploration, secure jurisdictions, and diversified project development.
• These updates underscore the company’s broader mission: building a multi-asset rare earths platform aligned with global supply chain realignment.

Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) is consolidating its efforts to execute its strategy of advancing a diverse portfolio of rare earth and critical metals projects across select geopolitically stable regions. Exploration updates from South and North America underscore the firm’s dual-pronged approach: the systematic advancement of priority assets toward resource definition and early-stage discovery, backed by strategic technical validation.

At the company’s Iron Hills Project in Gunnison County, Colorado, Canamera recently reported over-limit re-assay results that show high rare earth concentrations from its initial prospecting program. Follow-up sodium peroxide fusion analysis indicates a total rare earth oxide value of 6,557, including 2,336 ppm neodymium, a vital magnet rare earth element. Further samples showed heavy rare earth oxide values as much as 2,841, resulting from increased yttrium content (ibn.fm/8xYTX).

Six samples from the initial prospecting have so far returned TREO values more than 3,000 ppm. The frequency, strength, and elemental diversity of the results show a fertile rare earth system. The company’s management has highlighted that these results will help with follow-up work, including expanded sampling and the evaluation of airborne radiometric, magnetic, and electromagnetic surveys to better define mineralization controls.

Iron Hills is a vital American-based asset, especially at a time when domestic sources of rare earth metals are gaining traction. With the increased demand for wind energy, electric vehicles, and advanced electronics creating more need for magnet metals like neodymium, projects located in jurisdictions like Colorado come with strategic relevance.

In addition to this early-stage success, the company is also making significant progress through its Turvolândia rare earth project in Brazil, where Canamera is carrying out a maiden drill program. The first phase of drilling, comprising about 1,000 meters, will test the continuity and thickness of near-surface iconic clay-hosted rare earth mineralization across three core areas. This has attracted attention globally because of its potential for lower-cost extraction compared to what is obtainable with conventional hard-rock rare earth deposits (ibn.fm/aotFi).

Turvolândia is located close to the Poços de Caldas alkaline complex, an area quickly emerging as one of Brazil’s most prospective ionic clay rare earth districts. Early-stage drilling focuses on shallow auger holes aimed at weathered clay profiles developed over rare earth-enriched rocks, which are comparable to ion adsorption clay deposits that underpin much of the Chinese rare earth production.

The Turvolândia and Iron Hills updates highlight Canamera’s broader exploration thesis: identifying underexplored, district-scale opportunities spread across the Americas and promoting them using data-driven, methodical programs. The company’s operational portfolio also includes uranium and niobium projects in Wyoming, Ontario, and British Columbia, providing a diversified exposure across commodities and jurisdictions.

For more information, visit the company’s website at canamerametals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

• LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight against cancer.
• LIXTE develops LB-100, a drug that enhances the effectiveness of cancer treatments, while Liora has developed a unique cancer treatment that’s believed to be more affordable, precise, and efficient than many traditional options.
• Together, this pair of products have incredible clinical and commercial potential, to both help the businesses succeed, while also offering better outcomes for patients suffering from cancer.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined, have the potential to improve outcomes and results for cancer patients.

LIXTE’s flagship product and lead clinical candidate is LB-100, which is a proprietary small-molecule inhibitor of protein phosphatase 2A (“PP2A”). Designed to enhance the activity of chemotherapy and immunotherapy, the compound has developed a favorable safety profile in Phase 1 clinical trials and is supported by more than 25 published preclinical and translational studies.

The compound is currently being evaluated in multiple clinical programs that are targeting solid tumors with limited treatment options.

On the other hand, Liora Technologies develops the Linac for Image Guided Hadron Therapy (“LiGHT”) System. This system is a controlled proton therapy platform that offers many benefits over the other proton therapy methods currently available.

It can be deployed rapidly, is much smaller in size than other options, and is cheaper to build and use. The LiGHT System also works more efficiently as it reduces proton loss, allows for much more precise dosing, and allows you to change energy levels in milliseconds, not seconds. Also, the system controls beams electronically, which eliminates the needs for mechanical energy degraders, which often waste a ton of proton energy.

As you could imagine, there’s plenty of synergy between the two products – as the LB-100 enhances cancer therapies by making cancer cells more vulnerable, it takes an already efficient and powerful LiGHT system and makes it even more effective at fighting cancer. In addition to making cancer cells more susceptible to proton therapy and other types of radiation, LB-100 also stops them from being able to effectively recover after being damaged by the radiation.

This synergy not only helps deliver better outcomes for cancer patients, but also the businesses themselves. There aren’t many solutions out there in proton therapy like the LiGHT system, and the platform is a perfect match with LB-100. The combination could potentially be of great use clinically, which in turn boosts the commercial potential of the pairing, as well.

About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company developing cancer therapies. Instead of introducing standalone treatments, the company focuses on an approach to enhance the effectiveness of established therapies. The company’s work focuses on improving how treatments like chemotherapy and immunotherapy perform in difficult-to-treat cancers.

For more information, visit the company’s website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT